Wednesday, July 1, 2020, 5:00 PM – 6:00 PM ET

Recent Advances in Medical Oncology: Prostate Cancer


Robert Dreicer, MD, MS
Section Head, Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Daniel P Petrylak, MD
Professor of Internal Medicine (Medical Oncology) and Urology
Yale University
New Haven, Connecticut

Christopher Sweeney, MBBS
Professor, Medicine
Harvard Medical School
Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the ASCO20 Virtual Program. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

Module 1: Role of Androgen Receptor-Targeted Therapies in the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer (CRPC) — Daniel P Petrylak, MD

  • Structural composition, pharmacology, pharmacokinetics and pharmacodynamics of the next-generation antiandrogen agents apalutamide, darolutamide and enzalutamide
  • Design, eligibility criteria and key efficacy outcomes of the Phase III SPARTAN, ARAMIS and PROSPER trials evaluating apalut­amide, darolutamide and enzalutamide, respec­tively, for patients with nonmetastatic CRPC
  • Spectrum and frequency of toxicities, including CNS-related adverse events, associated with the use of apalutamide, darolutamide and enzalutamide in the SPARTAN, ARAMIS and PROSPER trials; rates of treatment discontinuation
  • FDA approvals of apalutamide, darolutamide and enzalutamide for nonmetastatic CRPC; patient selection and practical integration into clinical algorithms

Module 2: Optimal Management of Metastatic Hormone-Sensitive PC (mHSPC) — Christopher Sweeney, MBBS

  • Long-term efficacy and quality-of-life data with docetaxel or abiraterone and prednisone in combination with androgen deprivation therapy (ADT) for men with mHSPC
  • Design, entry criteria and primary and secondary endpoints of the Phase III ARCHES and TITAN trials comparing enzalutamide or apalutamide in combination with ADT to ADT alone for patients with mHSPC; key efficacy and safety outcomes
  • FDA approvals of enzalutamide and apalutamide for patients with mHSPC and optimal integration into clinical practice
  • Results from the Phase III ENZAMET study of enzalutamide in combination with ADT versus other nonsteroidal antiandrogens (bicalutamide, nilutamide or flutamide) with ADT for patients with mHSPC
  • Rationale for the inclusion of early docetaxel in the ENZAMET study; effect of earlier use of docetaxel on the efficacy and safety of enzalutamide
  • Relevant clinical, biologic and practical factors (eg, age, duration of therapy, extent and sites of metastases) guiding the selection of secondary hormonal therapy versus chemotherapy for mHSPC

Module 3: Treatment Strategies for Metastatic CRPC (mCRPC) — Robert Dreicer, MD, MS

  • Key efficacy and safety findings from the CARD study evaluating cabazitaxel versus alternative androgen receptor (AR)-targeted therapy (abiraterone or enzalutamide) for patients with mCRPC who had received docetaxel and experienced disease progression on a prior AR-targeted agent; implications for therapeutic sequencing
  • Patient selection for and optimal integration of radium-223 into current mCRPC treatment algorithms; ongoing evaluation of radium-223 in combination with other systemic therapies
  • Incidence of BRCA1/2 mutations and other DNA damage repair abnormalities (eg, ATM, PALB2) in patients with PC; rationale for and proposed mechanisms of antitumor activity of PARP inhibi­tors in metastatic PC
  • Available trial data with olaparib, rucaparib and niraparib for patients with progressive mCRPC
  • Recent FDA approval of rucaparib and olaparib for men with mCRPC; implications for genetic testing and routine practice
  • Preliminary findings from the mCRPC cohort of the Phase Ib COSMIC-021 trial evaluating cabozantinib in combination with atezolizumab; ongoing research and plans for development

Program Overview
Cancers of the genitourinary system affect hundreds of thousands of individuals within the United States each year and account for more than one fourth of all newly diagnosed human cancer cases. Of this diverse array of distinct diseases, tumors of the prostate are among the most prevalent and are thus the focus of extensive ongoing clinical research. A result of this research is that the clinical management of both early and more advanced presentations of prostate cancer (PC) is constantly evolving, necessitating rapid and consistent access to learning opportunities for clinicians. To provide these clinicians with therapeutic strategies to address the needs of patients, this CME webinar originally planned as a live symposium for the 2020 ASCO Annual Meeting uses the perspectives of a group of leading clinical investigators to address some of the most frequently encountered questions and controversies in the management of PC. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of PC with the formulation of up-to-date clinical management strategies.

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of PC.

Learning Objectives

  • Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant PC (CRPC), and apply this information in the discussion of nonresearch treatment options with patients.
  • Appraise the similarities and differences among commercially available next-generation antiandrogens in order to personalize therapy selection for patients.
  • Recognize the adverse effects associated with hormonal agents commonly employed in the management of PC, and develop strategies to prevent, mitigate and manage these toxicities.
  • Explore available data on the use of cytotoxic and secondary hormonal therapy for hormone-sensitive metastatic PC in order to effectively design treatment plans for appropriate patients.
  • Apply clinical research findings in the determination of best-practice selection and sequencing of available local and systemic treatment modalities for patients with metastatic CRPC.
  • Describe the rationale for testing patients with progressive CRPC for BRCA1/2 or other related mutations, and advise individuals found to harbor these genetic abnormalities about the FDA approvals and potential benefits of PARP inhibitors.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for PC, and counsel appropriate patients about availability and participation.

Competencies to Be Addressed
Patient Care and Procedural Skills and Medical Knowledge

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the conclusion of the activity.

Accreditation Statement
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

USF Health designates this live activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Privacy Disclosure
Learners provide permission for USF Health to share their completion data with ACCME, who will transmit same on their behalf to ABIM. Within 60 days of the end of the activity, USF Health will upload to ACCME the participant data of physicians who have met the ABIM MOC Points requirements; ACCME will transmit the same to ABIM.

Completion Requirements
Physicians seeking ABIM Points will be required to take an evaluation/post-test passing with a score of 80% or higher.

Disclosure Policy
USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

USF HEALTH CPD STAFF AND RESEARCH TO PRACTICE CME PLANNING COMMITTEE — Members, Staff, and Reviewers have no relevant conflicts to disclose.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr DreicerAdvisory Committee: Astellas, Eisai Inc, Janssen Biotech Inc, Novartis, Orion Corporation, Pfizer Inc, Seattle Genetics, Vizuri Health Sciences; Contracted Research: Bristol-Myers Squibb Company, Exelexis Inc, Pfizer Inc, Seattle Genetics. Dr PetrylakConsulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Endocyte Inc, Genentech, a member of the Roche Group, Innocrin Pharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics; Ownership Interest: Bellicum Pharmaceuticals Inc, Tyme Inc. Dr SweeneyConsulting Agreements: Astellas, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Lilly, Pfizer Inc, Sanofi Genzyme; Contracted Research: Astellas, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Pfizer Inc, Sanofi Genzyme.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

Equal Opportunity Statement
USF is an Equal Opportunity/Affirmative Action/Equal Access Institution.

Contact Information
If you have questions regarding credit, please contact, or call 813-224-7860.

This activity is supported by educational grants from Astellas and Pfizer Inc, Bayer HealthCare Pharmaceuticals, Exelixis Inc, and Sanofi Genzyme.